The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2

TACT-1 was a huge study that showed that chelation therapy can prevent future cardiac events for patients who had suffered a previous heart attack.  Chief Investigator, Dr. Gervasio Lamas, has published the study in major journals and presented the data at many medical schools across the U.S.  The most impressive part of the study was a 51% reduction in cardiac events in diabetic patients over a 5-year period.  The FDA was impressed as well, but they demand a confirmatory study for acceptance of chelation therapy.  Thus we now have TACT-2.  If you know anyone who is a diabetic and has had at least one heart attack, please have him or her contact our office to find out if they are eligible to participate in the study.  They would have a 2/3 probability of receiving $10,000 worth of treatment, without cost.

Call Celebration of Health Association at 800-788-4627.

Celebration of HealthAssociation website